Chip stocks fall with Nvidia after data center rev disappointment
Investing.com - RBC Capital initiated coverage on argenx SE (NASDAQ:ARGX) with an Outperform rating and a price target of $850.00 on Monday. According to InvestingPro data, the company maintains excellent financial health with a "GREAT" overall score, supported by robust revenue growth of 88% in the last twelve months.
The firm’s bullish stance comes despite argenx’s significant growth since 2022, when its stock more than doubled following the initial approval of its Vyvgart treatment.
RBC Capital conducted extensive research including a proprietary survey of 35 neurologists and six key opinion leader calls, which suggested Vyvgart’s uptake is likely to accelerate due to continued execution in approved indications, more convenient at-home administration options, and potential earlier use in treatment protocols.
The research also highlighted geographic expansion opportunities, noting that less than 15% of current revenues come from outside the United States, presenting significant growth potential for the $40 billion market cap company.
While RBC Capital acknowledged potential headwinds, including possible FDA action following cases of CIDP worsening and some gross-to-net challenges, the firm concluded these issues likely do not pose existential threats to argenx’s growth trajectory.
In other recent news, Argenx NV ADR reported outstanding financial results for the second quarter of 2025. The company achieved earnings per share of $6.32, which was more than double the anticipated $3.06, representing a 106.54% surprise. Additionally, Argenx’s revenue reached $1.74 billion, significantly exceeding the forecasted $876.3 million and marking a 98.56% surprise. These impressive results highlight the company’s strong financial performance and its ability to surpass market expectations. While there were no analyst upgrades or downgrades reported, the financial results alone have drawn considerable attention from investors. The robust earnings and revenue figures are central to recent developments surrounding Argenx.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.